Summary The goal of this study was to investigate the efficacy of photodynamic therapy (PDT) of a single tumour growing intraperitoneally. For this purpose the CC53 1 colon carcinoma, implanted in an intraperitoneal fat pad of Wag/RijA rats, was treated with intraperitoneal photodynamic therapy (IPPDT) using Photofrin as the photosensitiser. Two illumination techniques have been compared. An invasive illumination technique using Perspex blocks to illuminate 30 cm2 of the lower abdomen gave a significant delay in tumour growth with 25 J cm-2 applied 1 day after Photofrin. A minimally invasive illumination technique using a balloon catheter to illuminate 14 cm2 resulted in an equivalent growth delay with 75 J cm-2. The route of administration of the photosensitiser did not influence regrowth times of the tumour. Mitomycin C (MMC), a bioreductive agent, was used to exploit the known PDT-induced hypoxia. The combination of IPPDT with MMC resulted in an increased tumoricidal effect. In conclusion, IPPDT led to a significant growth delay for a single tumour implanted intraperitoneally and repetition of the PDT treatment was possible using a minimally invasive illumination technique. Repeated treatments resulted in increased tumour response.
The treatment of minimal residual peritoneal cancer is an ongoing oncological challenge because of the poor survival figures. About 35% of patients with microscopic residual disease from ovarian cancer survive 5 years (Neijt et al., 1991) . For patients with peritoneal metastases from colorectal cancer the median survival is between 3 and 12 months (Turnbull et al., 1989) . The multiple, small superficial tumours are usually confined to the peritoneum and should be suitable for local treatment. Photodynamic therapy (PDT) could be especially applicable for these peritoneally growing tumours, if illumination of the peritoneum can be achieved. PDT involves the systemic administration of a photosensitiser combined with local excitation of the photosensitiser, after a distribution interval. The photosensitiser is excited with light of a wavelength corresponding to an absorption peak of the sensitiser. The excited photosensitiser generates highly reactive toxic species (singlet oxygen and free radicals). The limited penetration depth of light used to excite Photofrin, the photosensitiser used in this study, restricts normal tissue toxicity to a maximum depth of about 1 cm. In small animal studies even this limited penetration depth can lead to substantial toxicity but the more bulky human organs will be relatively spared by their volume (DeLaney et al., 1993; Veenhuizen et al., 1994) .
Several preclinical studies have investigated the toxicity and efficacy of IPPDT in a variety of species. Haematoporphyrin derivative (HPD)-mediated IPPDT in rats appeared to disrupt intestinal blood flow (Selman et al., 1985) , although other studies demonstrated no serious damage to major blood vessels in rats treated with HPD mediated IPPDT (Suzuki et al., 1987) . In dogs, only mild inflammatory responses were found after treatment of the entire peritoneal cavity with 0.57-0.74 J cm-2 48 h after Photofrin (1.25 mg kg-') (Tochner et al., 1991) . In rabbits and baboons treated with HPD-mediated IPPDT, the liver and intestines appeared to be most sensitive to damage (Douglass et al., 1981) .
The first tumour results on IPPDT date from 1981 (Douglass et al., 1981) , where apparent necrosis of BrownPierce tumours in rabbits (implanted in serosa of the bowel, liver, pancreas or bladder) was reported 5 -7 days after treatment with HPD (5 mg kg-') and light. Red laser light (631 nm) was delivered through 200 gm diameter quartz glass fibres to illuminate a 1 cm diameter spot on the surface of the tumour. In this study extremely high fluences (300 J cm-2) and fluence rates (260-1400 mW cm-2) were used. Some hyperthermia was almost certainly associated with these treatments, which therefore cannot directly be compared with other studies. More clinically relevant studies are reported by Tochner et al. (1985, 1986) in which a murine ascites model was treated with HPD (50 mg kg-1) and 9.6 J of green (less penetrating) laser light of 514 nm wavelength. This treatment resulted in 6% cures after one PDT session and 37% and 85% cures after two and four PDT treatments respectively. In this study HPD was injected 2 h before each illumination. These results, together with the toxicity results in dogs, formed the basis for the only published phase I clinical trial for IPPDT to date (Sindelar et al., 1991; DeLaney et al., 1993) . This trial demonstrated the feasibility of delivering PDT to the peritoneal cavity at the time of laparotomy. Considering the limited available literature, we concluded that minimal residual peritoneal cancer presents an attractive challenge for IPPDT and that this is worthy of further investigation. In this study several IPPDT regimens were investigated in a rat tumour model. An intraperitoneal (i.p.) implantable colon carcinoma was used, since there is no rat ovarian carcinoma available. Intraperitoneal administration of the photosensitiser was studied with the aim of directly exposing the i.p. tumour to a high concentration of the photosensitiser. In addition, mitomycin C (MMC) was combined with PDT in an attempt to exploit the tumour hypoxia known to occur after PDT (Star et al., 1986; van Geel et al., 1994) . MMC is a cytostatic antibiotic that exerts its cytotoxicity by selectively inhibiting DNA synthesis (Verweij and Pinedo, 1990; Sartorelli, 1988) . Under hypoxic conditions the efficacy of MMC is 2-3 times greater than in oxic conditions (Rockwell, 1986) . Finally, the feasibility and efficacy of repeated IPPDT treatments were investigated using a minimal access illumination technique. The efficacy of IPPDT is compared with the best tested chemotherapy in this preclinical model: cisplatin. (Nagel et al., 1990) . The CC531 cells were grown in culture flasks in Dulbecco's modified Eagle medium (DMEM) with 10% fetal calf serum (FCS), penicillin and streptomycin. A single cell suspension was prepared by trypsinisation, counting in a haemocytometer, centrifuging (1000 r.p.m., 5 min) and suspending in phosphate-buffered saline (5 x 106 cells ml-'). This suspension (0.2 ml) was inoculated on the thigh of a donor rat. After 4-5 weeks a solid tumour with a diameter of 1-2 cm was developed. The tumour was excised and cut into slices of + 1.5 mm thickness. Cylinders of 3 mm diameter were punched from slices of the viable outer rim of the tumour. These cylinders were halved and kept in saline. Immediately after preparation the pieces were implanted in a fat pad in the lower abdomen of female Wag/RijA rats. The rats were anaesthetised with ether and the abdominal skin was shaved and cleaned with 70% ethanol. A median incision of 0.5-1.0 cm was made in the abdominal wall. A fat pad from the lower abdomen was gently pulled out and exposed on the abdominal wall, a tumour piece was placed on the fat pad and the fat was folded over the tumour and sutured with silk (5-0). The fat pad was replaced in the lower abdomen and the abdominal cavity was closed in one layer with 3-0 silk sutures. After 7 days the tumour had grown to a diameter of about 5 mm and was used for treatment.
Photosensitizers Photofrin (batch number: B91-0124, Lederle Etten-Leur, The Netherlands) was provided as a freeze-dried preparation, which was dissolved in 5% glucose to a concentration of 2 mg ml-'. The stock solution was then divided into aliquots and stored in the dark at -20°C until required (stock solutions were thawed and brought to room temperature once only before injection). Photofrin was given 24 h before illumination, at a dose of 5 mg kg-1, injected intravenously (i.v.) via tail vein. For i.p. injection the proper amount of photosensitiser per rat was dissolved in 3.5 ml of lukewarm saline 3 h or 24 h before illumination.
Chemotherapeutic drugs
The hypoxic toxin Mitomycin C (MMC, Kyowa, Christiaens Etten Leur, The Netherlands) was administered i.v. via the tail vein at a drug dose of 1.5 mg kg-'. MMC alone caused little acute toxicity (i.e. 3% weight loss in the first week). Postinjection flushing with saline ensured that MMC was not injected or spilled subcutaneously. Subcutaneous injection of MMC caused severe necrosis of the injection site leading to intolerable morbidity. Cisplatin (Platinol, Bristol-Myers Squibb Woerden, The Netherlands) was supplied as a solution of 0.5 mg ml-1 in 20 ml of sodium chloride 0.9% and hydrochloric acid in water at pH 2-3. Drug doses of 2 and 4 mg kg-1 (maximum tolerable) were used. Before i.p. injection cisplatin was dissolved in 13 -14 ml of lukewarm saline.
Illumination procedure For the initial series of experiments an invasive illumination procedure with Perspex light delivery blocks inserted into the lower abdomen was used (illumination protocol 1). This technique had the advantage that the light distribution over the entire lower abdomen could be accurately described for all tissues in direct contact with the blocks. The disadvantage of illumination protocol 1 was that it required large (5 cm) surgical incisions into the abdomen and was too invasive to be repeated. A second illumination procedure (protocol 2) was therefore also developed and tested, employing an inflatable balloon as the light source. This procedure had the advantage of being minimally invasive, thus permitting repeated treatments, but had the disadvantage of a less uniform light distribution over the lower abdomen. These two illumination procedures are described below.
Illumination protocol I Rats were anaesthetised with an intramuscular injection of 0.1 ml Aescoket plus (ketamine, xylazine and atropine) for illumination of the lower abdomen. They were kept warm (rectal temperature 35-38°C) on an electrical heating pad. A median incision of approximately 5 cm was made in the abdominal wall. The intestines were gently exteriorised and placed in a sterile saline moistened gauze during illumination. The tumour size was measured using vernier callipers. For illumination, two Perspex light delivery blocks were used as light dispersers. One block (3 x 2 x 1 cm) contained two cylindrical diffusing fibres (QLT Phototherapeutics, Pearl River, NY, USA) and the other block (3 x 1 x 1 cm) contained a single cylindrical diffusing fibre (diffusing tip 2 cm long, 1.7 mm diameter). The three fibres were coupled via a beam splitter to the dye laser (Spectra Physics model 373) pumped by a 23 W Argon laser (Spectra Physics model 171). Sulphorodamine B (Lambda Physik) was used as the dye to obtain red laser light of 628 + 3 nm. The wavelength of the emitted light was calibrated using a monochromator (Oriel model 77320). The output from each fibre was adjusted to 100 mW cm-1 diffusing length of the fibre (i.e. 200 mW per fibre), measured in an integrating sphere with an optical power meter UDT 371. For most experiments both blocks were placed in the lower abdomen (total surface area (SA) 30 cm2). In some experiments, however, only one block (containing two diffusing fibres) was used for illumination of the tumour area (illumination protocol lb). This gave an illumination SA of 20 cm2, which was similar to the illumination area from the minimally invasive illumination protocol 2 (see below). In situ dosimetry measurements, using an isotropic light detector coupled to an optical power meter, demonstrated a fluence rate of 100 + 8 mW cm-2 on the surface of the blocks when placed in the abdomen. During illumination, the tumour was placed in contact with the Perspex blocks. After illumination, the blocks were removed, the intestines were gently replaced and the abdominal wall was closed in one layer with silk sutures (3-0).
Illumination protocol 2 The rats were again anaesthetised with an intramuscular injection of Aescoket plus and rectal temperature was kept between 35 and 38°C using an electrical heating pad. A small (<5 mm) median incision was made just beneath the xiphoid process for the insertion of a balloon catheter (100% silicone elastomer, with an outer diameter of 3.7 mm Ch 12 Ruisch, Kernen, Germany 
Results Controls
For the control groups (no treatment, drug or light alone, sham operation) there was a maximum weight loss of 2% during the first 10 days. The tumour growth times for the four control groups did not differ significantly and the mean regrowth time for the four control groups was 20.4 (±1.4) days (Table II) . The possible influence of frequency of IPPDT using illumination protocol 1 Dose-finding studies with illumination protocol 1 (30 cm2 illuminated surface area), demonstrated that 75 J cm-2 given 24 h after Photofrin was just intolerable for tumour-bearing rats. Fluences of 50 and 25 J cm-2 were well tolerated and were therefore used in a first efficacy experiment. Both treatments resulted in a 4% weight loss in the first week with complete recovery within 2 weeks. These PDT schedules both resulted in longer regrowth times than control groups, significant for the 25 J cm-2 group; no light dose dependency was found within this dose range (see Figure 1 and Table III) .
Intraperitoneal administration of Photofrin was compared with i.v. administration for illumination intervals of 3 h and 1 day. No significant difference in tumour response was noted between the two injection routes for the 1 day interval (Table  II) (not included in regrowth times). tLethal toxicity.
the photosensitiser (P-values 0.042 and 0.026 respectively). The toxicity for the 3 h illumination interval was also increased (weight loss of 6% in the first week).
IPPDT combined with MMC MMC alone (1.5 mg kg-1) led to a significant increase in tumour regrowth time (27.9 vs 20.4 days). When light (25 J cm-2) was added to MMC there was a small, not significant, further increase in regrowth time to 32.8 days (see Table III ). Both these treatment schedules elicited the same moderate toxicity of 3% weight loss in the first week. When IPPDT was given within 15 min after the MMC injection, the regrowth time increased to 37.7 + 6.8 days and one cure was found. This was, however, not significantly different from IPPDT alone. The toxicity also increased to 5% weight loss in the first week. Recovery from this weight loss took 6 weeks in comparison with 2 weeks after PDT alone. Eight weeks after treatment, 15% of the animals treated with 1.5 mg kg-' MMC, singly or in combination, had developed a chemical alveolitis leading to intolerable morbidity.
Efficacy of minimally invasive illumination protocol 2 IPPDT using the single Perspex block illumination technique with a surface area of 20 cm2 (protocol lb) was compared with the minimally invasive technique using an inflatable balloon catheter (protocol 2; SA 14 cm2). The mean tumour regrowth time for a light dose of 25 J cm-2 using the invasive illumination protocol lb was in the range of the controls and less than the mean regrowth time after IPPDT with 25 J cm-2 delivered over the larger surface area with two Perspex blocks (protocol 1). Using the balloon catheter with the same total fluence (protocol 2), regrowth time increased to 28.0 + 3.7 days (the same range as protocol 1, large illumination surface area). The minimally invasive balloon catheter technique (protocol 2) was less toxic than the laparotomy block technique (protocol 1), so that higher light doses could be administered. (IPPDT using illumination protocol 2 with 75 J cm-2 gave only a 2% weight loss in the first week, whereas this light dose was not tolerated using protocol 1.) Increasing the light dose from 25 to 75 J cm-2 led to increased regrowth times with a significant difference relative to controls for 75 J cm-2 (Figure 1 ).
Single vs repeated IPPDT Tumour response to single or repeated treatments (balloon catheter illumination protocol 2) was compared using 1 and 2x 75 J cm-2 and 1, 2 or 4 x 50 J cm-2. Photofrin was given either as a single injection (5 mg kg-', i.v.) with illumination at 1 and 2 days (two treatments) or as 2 x 5 mg kg-' separated by 1 week, with illumination at 1 day after each drug dose (two treatments) or at 1 and 2 days after each drug dose (four treatments). Tumour growth curves after treatment with 1, 2 and 4 x 50 J cm-2 are shown in Figure  2 . Illumination with 2 x 50 J cm-2 with a 1 day interval gave a better tumour response (longer regrowth times) than a much larger than could be explained by additive toxicities (Tochner et al. 1985 (Tochner et al. : 1986 . To enable repeated PDT treatments to be given, the minimally invasive illumination protocol 2 w-as developed. The advantage of this technique is that it offers the possibility of repetition of the procedure with relatively short time intervals. Our results for the repeated IPPDT treatments demonstrated that a given light dose (50 J cm-') repeated at a short time interval (I day) led to a significant increase in grow-th delay w-ith respect to a single treatment. A larger interval of 1 w-eek appeared to be too long. possibly because in this w-eek the tumour has grown substantially (volume doubling time of this tumour is about 1 w-eek). The schedule of four illuminations (total light dose 200 J cm-) with two photosensitiser doses over a total time of 1 week was. however ver-effective and well tolerated.
To optimise IPPDT. the tumour to normal tissue photosensitiser ratio should be increased. To achieve this goal. the use of an immunoconjugate of the photosensitiser Photofrin does have an absorption peak at 514 nm and the use of this green (less penetrating light) might decrease toxicity and permit higher light doses to be given. but this w-ill only be suitable for very small tumours. Combinations of red and green light could offer the best chance for effective tumoncidal light doses to be delivered wAith acceptable toxicitv. In addition fractionation of illumination w-ith short time intervals may allow-normal tissues to recover before the tumour has regrown. All these strategies for optimisation need to be fully investigated in preclinical models before new clinical protocols are initiated.
In conclusion. IPPDT 
